Diabetic Neuropathy & Spinal Cord Stimulation: 5 Essential Facts

Meherab Ali
June 11, 2026

What it is, who it helps, and what the research really says

Spinal Cord Stimulation for Painful Diabetic Neuropathy

If you live with painful diabetic neuropathy, you have likely heard the usual options. Blood sugar control. Exercise. Foot care. A whole host of anti-neuropathic medications [10]. For many people, these help. For others, pain stays severe. It disrupts sleep, mood, mobility, and quality of life [1,3,7].

Spinal cord stimulation, or SCS, has gained attention for hard-to-treat diabetic neuropathy [1,2,7]. SCS uses a small device to send electrical signals near your spinal cord. Those signals aim to reduce how strongly your brain feels pain coming from your feet and legs [3].

This article explains what SCS is, who it tends to help, and what research shows about this diabetic neuropathy treatment option.

What is Spinal Cord Stimulation for Diabetic Neuropathy?

Spinal cord stimulation is a therapy in which a small implanted system delivers electrical pulses to nerves in the epidural space (an area right outside the spinal cord where pain signals can be modified) [3]. The goal is not to “erase” diabetic neuropathy, but to reduce the brain’s perception of pain signals coming from the affected areas, most often the feet and lower legs.

There are different SCS approaches. Two broad categories you may hear about are:

Traditional (low-frequency) SCS, which often produces a tingling pin and needle sensation (known as paresthesia) [3,7].
High-frequency SCS, which is designed to deliver pain relief without the same tingling sensation for many patients [1,3,7].

For painful diabetic neuropathy specifically, much of the strongest modern evidence is tied to high-frequency SCS [1,2,7].

Diabetic Neuropathy & Spinal Cord Stimulation — Source: https://www.mskcc.org/cancer-care/patient-education/about-your-spinal-cord-stimulator-scs

Who is a Candidate for Diabetic Neuropathy Treatment?

SCS is generally considered when:

Diabetic neuropathy commonly presents in a stocking-glove distribution, meaning symptoms typically begin in the feet and may later involve the hands (as if wearing socks or gloves) [1,3].
Pain has persisted despite conventional medical management (standard treatments like medication, glucose control, and supportive care) [1,2,4].
A specialist evaluation suggests you are a reasonable candidate (including medical suitability for a minor surgical procedure) [1,2,4].

Importantly, SCS is not typically a first-line treatment for diabetic neuropathy. It is more often discussed after standard options have not provided palpable relief [4,8]. Without consulting or trying other remedies, jumping ship straight to SCS can have a number of negative implications.

Furthermore, patient selection is critical: ideal candidates have chronic neuropathic pain lasting longer than six months, have tried at least two different medication classes without adequate relief, maintain reasonable blood sugar control, and have undergone psychological screening to ensure realistic expectations and the ability to manage the device [4,8].

What Does the Evidence Say?

The Big Randomized Clinical Trial (SENZA-PDN)

One of the most influential studies in this area is a large randomized clinical trial published in JAMA Neurology [1]. It compared conventional medical management alone versus high-frequency SCS plus conventional medical management in people with painful diabetic neuropathy, and found significantly better pain outcomes in the SCS group. A much larger proportion of people receiving high-frequency SCS achieved at least 50% pain relief without worsening nerve function compared with conventional management alone [1].

Systematic Reviews Confirm Effectiveness

A network meta-analysis published in Diabetes Care compared different types of SCS (including low-frequency and high-frequency) and found that both significantly reduced pain intensity compared to conventional medical management alone, with high-frequency SCS showing slightly superior pain relief outcomes for diabetic neuropathy [7]. An independent systematic review examining 14 prospective studies concluded there is moderate-quality evidence for the safety and efficacy of spinal cord stimulation for painful diabetic neuropathy [8].

Durability Over Time (24-Month and Long-Term Follow-Up)

A later 24-month follow-up publication from the same SENZA-PDN trial reported that benefits were maintained. Many participants reported substantial pain relief, along with improvements in sleep and health-related quality of life [2]. In this follow-up report, the mean pain reduction approached approximately 80% from baseline, and about 90% of participants experienced at least 50% pain relief [2]. However, device removal due to infection occurred in a small minority of cases [2]. Smaller follow-up studies extending out five to 10 years suggest that many patients who continue using the device maintain meaningful pain relief over time, though these reports are based on small subgroups of patients who still had functioning devices at follow-up and may not reflect outcomes across all patients who originally received SCS [9].

Safety and Regulatory Context

In the United States, the FDA publishes “Summary of Safety and Effectiveness Data” (SSED) documents — public reports that summarize what the FDA reviewed about a device’s benefits and risks [5]. For spinal cord stimulation systems expanded to include painful diabetic peripheral neuropathy, the SSED makes several practical points: implantation involves epidural lead placement (placing thin wires near the spinal cord) with an implanted pulse generator (a small battery/control device under the skin); it requires a successful trial because the system should not be used if a patient does not get effective pain relief via short trials; and it highlights major procedure-related risks such as infection and bleeding in the epidural space, which is higher for patients on blood thinners [5].

The SSED also notes that patients with diabetic peripheral neuropathy may have increased risk and adds warnings focused on managing risk factors such as poor blood sugar control, which can raise infection and healing risk [5]. Across the available trial and follow-up data, complications can include lead migration, loss of stimulation, and infection, with infections requiring device removal reported in roughly 3% of cases in the SENZA-PDN trial [2,8].

What Does Getting SCS Actually Involve?

Most SCS pathways include two phases:

1) The Trial

Before any permanent implant, many clinics do a trial stimulation period (often several days). Temporary leads (thin wires that deliver stimulation) are placed, and you track how your pain responds during normal life. The trial helps answer a key question:

“Do I get substantial pain relief from this approach?”

Not all patients achieve adequate pain relief during trial stimulation, and reported trial failure rates vary across studies and stimulation paradigms [8]. A failed trial means you avoid the risks and costs of a permanent implant that would not benefit you.

2) The Implant (If the Trial Works)

If the trial is successful, you may proceed to a permanent implant. This typically includes:

leads placed near the spinal cord (epidural space)
a small pulse generator (battery/control unit) implanted under the skin (often in the lower back or gluteal/upper buttock area).

Afterward, device settings are fine-tuned to optimize results.

Benefits People Report (When It Works)

Based on clinical trials and follow-up studies, people who respond to spinal cord stimulation for diabetic neuropathy often describe:

lower daily pain intensity [1,2,7]
better sleep [2,7]
improved function and quality of life [1,2,7,9]

Some studies also discuss neurological or sensory improvements in subsets of patients (some people report better sensation or function), though this should not be interpreted as guaranteed regeneration of nerves or nerve functions.

Risks and Downsides to Understand

SCS is not “minor” in the way a new cream or pill is. It involves procedures and an implanted device. Potential issues include:

infection (sometimes requiring device removal) [2,5,8]
lead movement or device problems (may require reprogramming, adjusting settings, or revision procedures — a follow-up procedure to fix or adjust the device)
discomfort at implant sites [5]
not achieving meaningful relief (even after trial, outcomes can vary over time) [3,8]

This is why careful patient selection, risk screening, and realistic expectations matter when considering spinal cord stimulation as a diabetic neuropathy treatment [4,5,8].

Questions to Ask Your Healthcare Team

If you are considering spinal cord stimulation for diabetic neuropathy, these are strong, practical questions:

Am I a candidate based on my neuropathy type and pain pattern?
What does “success” look like for the trial (for example, 50% pain reduction, improved sleep)?
Which device type are you recommending and why?
What are my personal infection risks and how do we reduce them?
What happens if the trial does not help?
How often will we follow up for programming and adjustments?
Will this affect MRI access or other future procedures? (depends on the exact device model) [5]

Key Takeaways

Spinal cord stimulation is a research-supported option for some people with refractory diabetic neuropathy pain that has not responded to standard treatments [1,2,4,7,8].
The strongest modern evidence for diabetic neuropathy includes a large randomized trial, systematic reviews, and longer-term follow-up for 10 kHz SCS, showing durable pain relief for many participants [1,2,7,8,9].
Like any implantable therapy, SCS comes with real risks, including infection, and requires careful selection and follow-up [2,4,5,8].
While initial costs are substantial, early data show that SCS may reduce some healthcare costs through decreased hospitalizations and medication use, though longer-term cost data are still limited [6].
For people living with diabetic neuropathy, it is best viewed as one tool in a broader plan that still includes diabetes management, activity as tolerated, and individualized pain care [3,4].